
Integrated Pipeline for Systems Pharmacology in R/Bioconductor

Nan Xiao @road2stat 7th China R Beijing



2009 Vulnerability & Security

2013 Web Scraping with R

2014 Systems Pharmacology

时间都去哪儿了






Outline

- Intro: Systems Pharmacology
- Pipeline: Our solution with R
- Case study: Identify novel drug-ADR associations

Part I Systems Pharmacology

Flow of Information in a Drug Discovery Pipeline



The Evolution of the Innovation


The Facts

Reductionism

- Key Lock Model
- Clean Drug
- One drug, one target, one disease

System Theory


- Systems Pharmacology
- Network Pharmacology
- Systems Biology




Yildirim, M.A., Goh, k.-I,. Cusick, M.E., Barabasi, A.-I & Vidal, M. (2007) Nat. Biotech. 25, 1119-1126.

Big Data, Small Details

M. Sirota et al., Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3 (2011).



Pipeline of Systems Pharmacology



Academic

- Application of systems biology approaches
- Combining large-scale experimental studies
- Model-based computational analyses to study drug activities, targets, and effects

Industry

- Using pharmacodynamic (PD) and pharmacokinetic (PK) modelling
- Predicting dose-exposure responses and evaluating market potential

NIH White Paper by the QSP Workshop Group (Oct, 2011)

Biology's Dry Future


The explosion of publicly available databases housing sequences, structures, and images allows life scientists to make fundamental discoveries without ever getting their hands "wet" at the lab bench

Science (2013) 342, 186-189.



"I'm like a kid in a candy store.


There is so much we can do."



"You basically **don't need a wet lab** to explore biology."

—David Heckerman, Microsoft Research

—Atul Butte, Stanford University School of Medicine



Integration-based systematic thinking, is the core of QSP.



THE 'OMES PUZZLE

Where once there was the genome, now there are thousands of 'omes.

It's a trend to integrate the Omics data, numerical or non-numerical, structural or non-structural, semantic or non-semantic.

Nature (2013) 494, 416-419.

Emerging

Established

GENOME
The genetic
material of an

organism

TRANSCRIPTOME All RNA expressed

from the genome

PROTEOME
All the proteins in a system

METABOLOME All the small molecules in a system

VARIOME All genetic

All genetic variation across a population

EPIGENOME All elements controlling gene expression not encoded in DNA

INTERACTOME
All the molecular interactions in a system

FLUXOME
Dynamics of small molecules over time

. .

PHENOME Complete physical descriptions that

can ideally be related to genotype

REGULOME

All the regulatory elements in a cell

INTEGROME


A combination of multiple 'omics data sets


OMNISCIOME*

The entirety of knowledge about a cell, organism or system

The Dawn of A New Era: Bio Big Data Blossom

Drugbank Database







1179 FDA-approved small molecule & biotech drugs (different chemical entities)

890 / 1179 has human protein targets390 Human Drug Target Proteins for Approved Drugs.

Wishart DS et al., Nucleic Acids Res. 2006 1;3

Drug-Target






UniProt Database




The mission of UniProt is to provide the scientific community with a comprehensive, high-quality and freely accessible resource of protein sequence and functional information.


BioGRID Database



BioGRID is an online interaction repository with data compiled through comprehensive curation efforts. The current index searches 41,785 publications for 722,541 raw protein and genetic interactions from major model organism species.

CTD Database





The Comparative Toxicogenomics Database (CTD) provides information about interactions between environmental chemicals and gene products and their relationships to diseases. Chemical-gene, chemical-disease and gene-disease interactions manually curated from the literature are integrated.

SIDER Database

Browse the drugs by name:

| aba-ami | aml-bec | ben-cab | caf-cef | cel-clo | coc-den | lev-mef | meg-met | mex-nap | nar-olm | olo-per | phe-pra

Browse the side effects by name:

| 5q -abn | abo-acr | act-acu | add-agi | agn-alo | alt-ana | anc-ano | ant-abin-ble | bli | blo | blu-bra | bre | bro-bul | bun-cap | car | cas-cen | cer-ce | coo-cox | cra-cut | cya-dea | dec-den | dep-det | dev-dia | dif-diu | div-dry | cra-ava | ava-ava | fac-fat | fac-fit | fits foo | for-asp | face | facu-gig | gin-ce


Downloading data

Here, you can download the current version versions can be found on the FTP site.

Mapping of labels

The package inserts contain information about information, labels were mapped to STITCH identifiers. (These compound identifiers mig vears.)

Information



More information: STITCH, PubChem and possibly Wikipedia or Medpedia

jun-lab

ATC Codes: A01AD05, B01AC06, N02BA01

SIDER contains information on marketed medicines and their recorded ADRs. The information is extracted from public documents and package inserts. It contains 99423 drug-ADR pairs associated with 996 drugs and 4192 ADRs.


Michael Kuhn et al., Molecular Systems Biology 2010 (6) 1-6

Side effect	Data for drug	Placebo Labels	
		1 2345	
Dyspnoea def	28%		
Headache def	18%		
Dizziness def	12%		
Lightheadedness	12%		
Hypotension def	2%		
Arrhythmia def	1%		
Bronchospasm def	postmarketing		
Grand mal convulsion def	postmarketing		
Cardiac arrest def	postmarketing		
Seizures def	postmarketing		
Torsade de pointes def	postmarketing		
Loss of consciousness de	postmarketing		
Ventricular fibrillation def	postmarketing		
Bradycardia def	postmarketing		
Blood pressure increased	postmarketing		

		Number of drugs	and side effects			
# of SE	# of drugs	# of drug-SE pairs	Pairs with frequency information			
4192	996	99423	40.8%			
	Number of	drug-side effect pair	s in different frequen	cy ranges		
	frequent (with exact data)	infrequent (with exact data)	rare (with exact data)	postmarketing	total	
drug	11475 (10316)	9471 (3236)	6650 (2068)	21664	40603	
placebo	4330 (4330)	2043 (2043)	1425 (1425)	0	6370	

provides access to preferred terms and lower-level terms. The number of drugs has increased from 888 to 996. Compared to the release in March 2012, additional side effects have been retrieved by better processing of the labels. Side effects that are mentioned on the label as either potential or not occurring are removed. SIDER 1 is still available via FTP.

CHALLENGE ACCEPTED



Part II Packages & Web Servers

What do we need for Systems Pharmacology Modeling?

- Information: Multi-scale Representation
- Methodology: Multi-scale Modeling

What does R need?

- Good at methodology and modeling, state-of-art statistical machine learning methods, Bioconductor
- Lacks of bio/chem data representation
- A good representation is fundamental and critical


What we did?

R/Bioconductor packages for

multi-scale molecular representation

protr

Protein Sequence Descriptor Calculation and Similarity Computation with R



Schematic diagram of the protr package. from Xiao et al., (2014)


What could protr do?

- For regular predictive modeling
 - 14 types of commonly used descriptors:
 - Bioinformatics (Classification)
 - 6 types of PCM descriptors:
 - Proteochemometrics (Regression)

What could protr do?

- For similarity-based modeling methods
 - Similarity derived by sequence alignment & GO:
 - Similarity-based clustering
 - Kernel methods
 - etc.


Make protein sequence into a numerical vector



For algorithmic details, see vignette('protr')

ProtrWeb


- Shiny-based
- Fast implementation: 1 Day



A Screenshot of ProtrWeb


Rcpi


R/Bioconductor Package for Bioinformatics, Chemoinformatics & Chemogenomics Research



Schematic diagram of the Rcpi package. from Xiao et al., (2014)

What could Rcpi do?





Arc diagram of the GPCR drug-target interaction network from Xiao et, al. (2014)

Experience & Pitfalls

Dependency Hell

- foreach / doParallel / doMC
- Biostrings
- GOSemSim
- ChemmineR
- ChemmineOB
- fmcsR
- rcdk
- RCurl



Checking Hell

- R CMD check
- BiocCheck



Experiences

- Use Roxygen2 to generate docs and NAMESPACE
- Cross-platform availability: doParallel / doMC
- Unit Tests

Part III Drug-ADR Prediction

Identify Novel Drug-ADR Associations

- Integrated multiple evidence from multiple levels
- Collaborative filtering and link prediction
- Mainly done by R, some done by Python

Summary

Summary

- Integrating only in the molecular structure level for now
- With R's modelling capability, applications promised.

Future Works

- protr: Incorporate protein 3D information
- Rcpi: Integration of RDKit, ChemoPy
- Omics Information (Genome / Proteome / Phenome)
- Network-based representations

Our Vision

- Systematic integration
- Comprehensive pipeline

Resources

protr

http://cran.r-project.org/web/packages/protr/

Rcpi

http://bioconductor.org/packages/release/bioc/html/Rcpi.html

ProtrWeb

http://cbdd.csu.edu.cn:8080/protrweb/

有时,整个地球结盟促进某些幸运的学科发展,而那些学科也随之绽放出新思想的花蕾、取得惊人的进展。而关键在于,哪里有大量累积起来的关于这个领域的有意义的问题,并且总有新技术应用于该领域,使得更加贴近的观察那些过程成为可能。

现在这个星球也许正在联合起来促进统计学的发展。新技术——电子计算技术,打破了曾限制了传统统计理论发展的计算瓶颈。同时,一类重要问题的洪流正奔向我们,其表现形式为大型数据集以及大规模推断问题。我相信,这一代统计学家将投身于一个新的统计创新年代,一个可与 Fisher、Neyman、Hotelling 以及 Wald 的黄金时代相媲美的时代。

Sometimes, not very often, the planets align for some lucky discipline, which then blossoms with new ideas and breath-taking progress. Microbiology is a perfect current example. The key there was a buildup of interesting questions concerning cellular processes, followed by new technology that enabled a much closer look at those processes in action.

Now the planets may be aligning for statistics. New technology, electronic computation, has broken the bottleneck of calculation that limited classical statistical theory. At the same time an onrush of important new questions has come upon us, in the form of huge data sets and large-scale inference problems. I believe that the statisticians of this generation will participate in a new age of statistical innovation that might rival the golden age of Fisher, Neyman, Hotelling, and Wald.

Q & A